{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T06:06:08Z","timestamp":1780380368791,"version":"3.54.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T00:00:00Z","timestamp":1633996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T00:00:00Z","timestamp":1633996800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe cutaneous adverse drug reactions with high mortality rates. Its sequelae, such as blindness, persist even after recovery. Patients with SJS\/TEN should be accurately diagnosed and receive appropriate treatment as soon as possible. Therefore, identifying the factors for severity prediction is necessary. We aimed to clarify the clinical parameters and biological markers that can predict acute severe ocular complications (SOCs) in SJS\/TEN. This retrospective cross-sectional study enrolled 47 patients with SJS\/TEN who were divided into two groups according to ocular severity at acute onset: non-severe ocular complications group (n\u2009=\u200927) and severe ocular complications group (n\u2009=\u200920). Multivariate logistic regression analysis revealed that disease severity (body surface area detachment\u2009\u2265\u200910%) was a predictive factor for acute SOCs, and older age (\u2265\u200960\u00a0years) was marginally significantly predictive of SOCs. Serum biomarker levels of S100A8\/A9 and granulysin were marginally significant and tended to increase in the SOC group. Therefore, during the early acute stage, focusing on disease severity, patient age, and serum inflammatory biomarkers (S100A8\/A9 and granulysin) might help predict SOC progression in patients with SJS\/TEN who need prompt and aggressive ocular management to prevent severe ocular sequelae.<\/jats:p>","DOI":"10.1038\/s41598-021-99370-1","type":"journal-article","created":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T13:24:52Z","timestamp":1634045092000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Clinical parameters and biological markers associated with acute severe ocular complications in Stevens-Johnson syndrome and toxic epidermal necrolysis"],"prefix":"10.1038","volume":"11","author":[{"given":"Rawiphan","family":"Panpruk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vilavun","family":"Puangsricharern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jettanong","family":"Klaewsongkram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawinee","family":"Rerknimitr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanachaporn","family":"Kittipibul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuda","family":"Chongpison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supranee","family":"Buranapraditkun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,12]]},"reference":[{"key":"99370_CR1","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1001\/archderm.1993.01680220104023","volume":"129","author":"S Bastuji-Garin","year":"1993","unstructured":"Bastuji-Garin, S. et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens\u2013Johnson syndrome, and erythema multiforme. Arch. Dermatol. 129, 92\u201396 (1993).","journal-title":"Arch. Dermatol."},{"key":"99370_CR2","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.ophtha.2008.12.048","volume":"116","author":"C Sotozono","year":"2009","unstructured":"Sotozono, C. et al. Diagnosis and treatment of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis with ocular complications. Ophthalmology 116, 685\u2013690 (2009).","journal-title":"Ophthalmology"},{"key":"99370_CR3","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1046\/j.1523-1747.2000.00061.x","volume":"115","author":"S Bastuji-Garin","year":"2000","unstructured":"Bastuji-Garin, S. et al. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J. Invest. Dermatol. 115, 149\u2013153 (2000).","journal-title":"J. Invest. Dermatol."},{"key":"99370_CR4","doi-asserted-by":"publisher","first-page":"419","DOI":"10.2332\/allergolint.O-07-483","volume":"56","author":"Y Yamane","year":"2007","unstructured":"Yamane, Y., Aihara, M. & Ikezawa, Z. Analysis of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis in Japan from 2000 to 2006. Allergol. Int. 56, 419\u2013425 (2007).","journal-title":"Allergol. Int."},{"key":"99370_CR5","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s12016-017-8654-z","volume":"54","author":"M Lerch","year":"2018","unstructured":"Lerch, M., Mainetti, C., Terziroli Beretta-Piccoli, B. & Harr, T. Current perspectives on stevens-johnson syndrome and toxic epidermal necrolysis. Clin. Rev. Allerg. Immunol. 54, 147\u2013176 (2018).","journal-title":"Clin. Rev. Allerg. Immunol."},{"key":"99370_CR6","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1007\/s40264-019-00825-2","volume":"42","author":"T Bell\u00f3n","year":"2019","unstructured":"Bell\u00f3n, T. Mechanisms of severe cutaneous adverse reactions: recent advances. Drug Saf. 42, 973\u2013992 (2019).","journal-title":"Drug Saf."},{"key":"99370_CR7","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.ajo.2010.04.026","volume":"150","author":"ME Morales","year":"2010","unstructured":"Morales, M. E., Purdue, G. F., Verity, S. M., Arnoldo, B. D. & Blomquist, P. H. Ophthalmic manifestations of stevens-johnson syndrome and toxic epidermal necrolysis and relation to SCORTEN. Am. J. Ophthalmol. 150, 505\u2013510 (2010).","journal-title":"Am. J. Ophthalmol."},{"key":"99370_CR8","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1016\/j.ophtha.2016.04.041","volume":"123","author":"DG Gregory","year":"2016","unstructured":"Gregory, D. G. New Grading system and treatment guidelines for the acute ocular manifestations of Stevens\u2013Johnson syndrome. Ophthalmology 123, 1653\u20131658 (2016).","journal-title":"Ophthalmology"},{"key":"99370_CR9","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1097\/00007611-198005000-00015","volume":"73","author":"JZ Yetiv","year":"1980","unstructured":"Yetiv, J. Z., Bianchine, J. R. & Owen, J. A. Jr. Etiologic factors of the Stevens\u2013Johnson syndrome. South Med. J. 73, 599\u2013602 (1980).","journal-title":"South Med. J."},{"key":"99370_CR10","first-page":"157","volume":"145","author":"J Gueudry","year":"2009","unstructured":"Gueudry, J., Roujeau, J. C., Binaghi, M., Soubrane, G. & Muraine, M. Risk factors for the development of ocular complications of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis. Arch. Dermatol. 145, 157\u2013162 (2009).","journal-title":"Arch. Dermatol."},{"key":"99370_CR11","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.ophtha.2014.08.013","volume":"122","author":"DH Kim","year":"2015","unstructured":"Kim, D. H. et al. The role of systemic immunomodulatory treatment and prognostic factors on chronic ocular complications in Stevens\u2013Johnson syndrome. Ophthalmology 122, 254\u2013264 (2015).","journal-title":"Ophthalmology"},{"key":"99370_CR12","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.ophtha.2010.06.035","volume":"118","author":"JS Lopez-Garcia","year":"2011","unstructured":"Lopez-Garcia, J. S. et al. Ocular features and histopathologic changes during follow-up of toxic epidermal necrolysis. Ophthalmology 118, 265\u2013271 (2011).","journal-title":"Ophthalmology"},{"key":"99370_CR13","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/j.ajo.2008.12.040","volume":"147","author":"Y Araki","year":"2009","unstructured":"Araki, Y. et al. Successful treatment of Stevens\u2013Johnson syndrome with steroid pulse therapy at disease onset. Am. J. Ophthalmol. 147, 1004\u20131011 (2009).","journal-title":"Am. J. Ophthalmol."},{"key":"99370_CR14","doi-asserted-by":"crossref","unstructured":"Ma, D.H.-K. et al. Clinical Aspects of Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis with severe ocular complications in Taiwan. Front. Med. 8(2021).","DOI":"10.3389\/fmed.2021.661891"},{"key":"99370_CR15","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1001\/archopht.1973.01000050378008","volume":"90","author":"MJ Arstikaitis","year":"1973","unstructured":"Arstikaitis, M. J. Ocular aftermath of Stevens\u2013Johnson syndrome. Arch. Ophthalmol. 90, 376\u2013379 (1973).","journal-title":"Arch. Ophthalmol."},{"key":"99370_CR16","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.jaci.2015.05.050","volume":"136","author":"KD White","year":"2015","unstructured":"White, K. D., Chung, W. H., Hung, S. I., Mallal, S. & Phillips, E. J. Evolving models of the immunopathogenesis of T cell-mediated drug allergy: the role of host, pathogens, and drug response. J. Allergy Clin. Immunol. 136, 219\u2013234 (2015).","journal-title":"J. Allergy Clin. Immunol."},{"key":"99370_CR17","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.jtos.2015.10.002","volume":"14","author":"S Kohanim","year":"2016","unstructured":"Kohanim, S. et al. Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis\u2013a comprehensive review and guide to therapy. I. Systemic disease.  The Ocular Surf. 14, 2\u201319 (2016).","journal-title":"The Ocular Surf."},{"key":"99370_CR18","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1111\/jdv.16339","volume":"34","author":"EC Kuijper","year":"2020","unstructured":"Kuijper, E. C., French, L. E., Tensen, C. P., Vermeer, M. H. & Bouwes Bavinck, J. N. Clinical and pathogenic aspects of the severe cutaneous adverse reaction epidermal necrolysis (EN). J. Eur. Acad. Dermatol. Venereol. 34, 1957\u20131971 (2020).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"99370_CR19","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1136\/bjo.2006.113241","volume":"91","author":"GP Williams","year":"2007","unstructured":"Williams, G. P., Mudhar, H. S. & Leyland, M. Early pathological features of the cornea in toxic epidermal necrolysis. Br. J. Ophthalmol. 91, 1129\u20131132 (2007).","journal-title":"Br. J. Ophthalmol."},{"key":"99370_CR20","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1136\/bjo.2010.196295","volume":"95","author":"T Yagi","year":"2011","unstructured":"Yagi, T. et al. Cytokine storm arising on the ocular surface in a patient with Stevens-Johnson syndrome. Br. J. Ophthalmol. 95, 1030\u20131031 (2011).","journal-title":"Br. J. Ophthalmol."},{"key":"99370_CR21","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1111\/j.1365-2133.2006.07398.x","volume":"155","author":"M Caproni","year":"2006","unstructured":"Caproni, M. et al. Expression of cytokines and chemokine receptors in the cutaneous lesions of erythema multiforme and Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis. Br. J. Dermatol. 155, 722\u2013728 (2006).","journal-title":"Br. J. Dermatol."},{"key":"99370_CR22","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1016\/j.jaci.2004.07.047","volume":"114","author":"A Nassif","year":"2004","unstructured":"Nassif, A. et al. Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. J. Allergy Clin. Immunol. 114, 1209\u20131215 (2004).","journal-title":"J. Allergy Clin. Immunol."},{"key":"99370_CR23","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.jid.2016.11.034","volume":"137","author":"SC Su","year":"2017","unstructured":"Su, S. C. et al. Interleukin-15 Is associated with severity and mortality in Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis. J. Invest. Dermatol. 137, 1065\u20131073 (2017).","journal-title":"J. Invest. Dermatol."},{"key":"99370_CR24","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.4049\/jimmunol.1602144","volume":"199","author":"Y Chen","year":"2017","unstructured":"Chen, Y. et al. IFN-\u03b3-expressing Th17 cells are required for development of severe ocular surface autoimmunity. J. Immunol. 199, 1163\u20131169 (2017).","journal-title":"J. Immunol."},{"key":"99370_CR25","doi-asserted-by":"publisher","first-page":"107602962095083","DOI":"10.1177\/1076029620950831","volume":"27","author":"M Sadek","year":"2021","unstructured":"Sadek, M. et al. The Role of IL-13, IL-15 and granulysin in the pathogenesis of Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis. Clin. Appl. Thromb. Hemost. 27, 1076029620950831 (2021).","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"99370_CR26","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1038\/nm.1884","volume":"14","author":"WH Chung","year":"2008","unstructured":"Chung, W. H. et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens\u2013Johnson syndrome and toxic epidermal necrolysis. Nat. Med. 14, 1343\u20131350 (2008).","journal-title":"Nat. Med."},{"key":"99370_CR27","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ajo.2015.05.002","volume":"160","author":"C Sotozono","year":"2015","unstructured":"Sotozono, C. et al. Predictive factors associated with acute ocular involvement in Stevens\u2013Johnson syndrome and toxic epidermal necrolysis. Am. J. Ophthalmol. 160, 228\u2013237 (2015).","journal-title":"Am. J. Ophthalmol."},{"key":"99370_CR28","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.annder.2018.01.040","volume":"145","author":"B Saka","year":"2018","unstructured":"Saka, B. et al. Factors associated with the severity of acute ocular involvement in Stevens\u2013Johnson syndrome and toxic epidermal necrolysis in sub-Saharan Africa. Ann. Dermatol. Venereol. 145, 245\u2013249 (2018).","journal-title":"Ann. Dermatol. Venereol."},{"key":"99370_CR29","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/j.1398-9995.2006.01295.x","volume":"62","author":"LW Yip","year":"2007","unstructured":"Yip, L. W. et al. Ocular manifestations and complications of Stevens-Johnson syndrome and toxic epidermal necrolysis: an Asian series. Allergy 62, 527\u2013531 (2007).","journal-title":"Allergy"},{"key":"99370_CR30","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1016\/S0161-6420(95)30811-1","volume":"102","author":"WJ Power","year":"1995","unstructured":"Power, W. J., Ghoraishi, M., Merayo-Lloves, J., Neves, R. A. & Foster, C. S. Analysis of the acute ophthalmic manifestations of the erythema multiforme\/Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis disease spectrum. Ophthalmology 102, 1669\u20131676 (1995).","journal-title":"Ophthalmology"},{"key":"99370_CR31","first-page":"1582","volume":"37","author":"SE Wilson","year":"1996","unstructured":"Wilson, S. E. et al. The Fas\u2013Fas ligand system and other modulators of apoptosis in the cornea. Invest. Ophthalmol. Vis. Sci. 37, 1582\u20131592 (1996).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"99370_CR32","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1126\/science.282.5388.490","volume":"282","author":"I Viard","year":"1998","unstructured":"Viard, I. et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 282, 490\u2013493 (1998).","journal-title":"Science"},{"key":"99370_CR33","doi-asserted-by":"publisher","first-page":"4862","DOI":"10.1038\/srep04862","volume":"4","author":"M Ueta","year":"2014","unstructured":"Ueta, M. et al. Independent strong association of HLA-A*02:06 and HLA-B*44:03 with cold medicine-related Stevens\u2013Johnson syndrome with severe mucosal involvement. Sci. Rep. 4, 4862 (2014).","journal-title":"Sci. Rep."},{"key":"99370_CR34","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1136\/bjophthalmol-2017-311823","volume":"102","author":"P Jongkhajornpong","year":"2018","unstructured":"Jongkhajornpong, P. et al. Association between HLA-B*44:03-HLA-C*07:01 haplotype and cold medicine-related Stevens\u2013Johnson syndrome with severe ocular complications in Thailand. Br. J. Ophthalmol. 102, 1303\u20131307 (2018).","journal-title":"Br. J. Ophthalmol."},{"key":"99370_CR35","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.3389\/fimmu.2018.01298","volume":"9","author":"S Wang","year":"2018","unstructured":"Wang, S. et al. S100A8\/A9 in inflammation. Front. Immunol. 9, 1298 (2018).","journal-title":"Front. Immunol."},{"key":"99370_CR36","first-page":"2476","volume":"20","author":"MJ Kim","year":"2019","unstructured":"Kim, M. J. et al. Effect of S100A8 and S100A9 on expressions of cytokine and skin barrier protein in human keratinocytes. Mol. Med. Rep. 20, 2476\u20132483 (2019).","journal-title":"Mol. Med. Rep."},{"key":"99370_CR37","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/nm.2150","volume":"16","author":"K Loser","year":"2010","unstructured":"Loser, K. et al. The Toll-like receptor 4 ligands Mrp8 and Mrp14 are crucial in the development of autoreactive CD8+ T cells. Nat. Med. 16, 713\u2013717 (2010).","journal-title":"Nat. Med."},{"key":"99370_CR38","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1097\/00000372-200010000-00005","volume":"22","author":"P Paquet","year":"2000","unstructured":"Paquet, P. et al. Immunoregulatory effector cells in drug-induced toxic epidermal necrolysis. Am. J. Dermatopathol. 22, 413\u2013417 (2000).","journal-title":"Am. J. Dermatopathol."},{"key":"99370_CR39","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1038\/jid.2010.158","volume":"130","author":"A Abtin","year":"2010","unstructured":"Abtin, A. et al. The antimicrobial heterodimer S100A8\/S100A9 (calprotectin) is upregulated by bacterial flagellin in human epidermal keratinocytes. J. Invest. Dermatol. 130, 2423\u20132430 (2010).","journal-title":"J. Invest. Dermatol."},{"key":"99370_CR40","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1016\/j.celrep.2017.02.004","volume":"18","author":"EL Goldberg","year":"2017","unstructured":"Goldberg, E. L. et al. \u03b2-hydroxybutyrate deactivates neutrophil NLRP3 inflammasome to relieve gout flares. Cell Rep. 18, 2077\u20132087 (2017).","journal-title":"Cell Rep."},{"key":"99370_CR41","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1177\/0300060515598900","volume":"44","author":"MS Chimenti","year":"2016","unstructured":"Chimenti, M. S. et al. S100A8\/A9 in psoriatic plaques from patients with psoriatic arthritis. J. Int. Med. Res. 44, 33\u201337 (2016).","journal-title":"J. Int. Med. Res."},{"key":"99370_CR42","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/emboj.2012.309","volume":"32","author":"B Petersen","year":"2013","unstructured":"Petersen, B. et al. The alarmin Mrp8\/14 as regulator of the adaptive immune response during allergic contact dermatitis. Embo J. 32, 100\u2013111 (2013).","journal-title":"Embo J."},{"key":"99370_CR43","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1111\/j.1523-1747.2003.12629.x","volume":"121","author":"C Marionnet","year":"2003","unstructured":"Marionnet, C. et al. Modulation of gene expression induced in human epidermis by environmental stress in vivo. J. Invest. Dermatol. 121, 1447\u20131458 (2003).","journal-title":"J. Invest. Dermatol."},{"key":"99370_CR44","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jtos.2013.10.001","volume":"12","author":"L Tong","year":"2014","unstructured":"Tong, L., Lan, W., Lim, R. R. & Chaurasia, S. S. S100A proteins as molecular targets in the ocular surface inflammatory diseases. Ocul Surf. 12, 23\u201331 (2014).","journal-title":"Ocul Surf."},{"key":"99370_CR45","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1167\/iovs.12-10172","volume":"54","author":"Q Deng","year":"2013","unstructured":"Deng, Q. et al. MRP8\/14 enhances corneal susceptibility to Pseudomonas aeruginosa Infection by amplifying inflammatory responses. Invest. Ophthalmol. Vis. Sci. 54, 1227\u20131234 (2013).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"99370_CR46","doi-asserted-by":"publisher","first-page":"7653","DOI":"10.1167\/iovs.15-17066","volume":"56","author":"K Walscheid","year":"2015","unstructured":"Walscheid, K. et al. Elevated S100A8\/A9 and S100A12 Serum levels reflect intraocular inflammation in juvenile idiopathic arthritis-associated uveitis: results from a pilot study. Invest. Ophthalmol. Vis. Sci. 56, 7653\u20137660 (2015).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"99370_CR47","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jdermsci.2007.05.013","volume":"48","author":"D Nishio","year":"2007","unstructured":"Nishio, D., Izu, K., Kabashima, K. & Tokura, Y. T cell populations propagating in the peripheral blood of patients with drug eruptions. J. Dermatol. Sci. 48, 25\u201333 (2007).","journal-title":"J. Dermatol. Sci."},{"key":"99370_CR48","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1067\/mjd.2002.120473","volume":"47","author":"O Correia","year":"2002","unstructured":"Correia, O., Delgado, L., Barbosa, I. L., Campilho, F. & Fleming-Torrinha, J. Increased interleukin 10, tumor necrosis factor alpha, and interleukin 6 levels in blister fluid of toxic epidermal necrolysis. J. Am. Acad. Dermatol. 47, 58\u201362 (2002).","journal-title":"J. Am. Acad. Dermatol."},{"key":"99370_CR49","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1080\/09273948.2016.1277247","volume":"26","author":"H Ghasemi","year":"2018","unstructured":"Ghasemi, H. Roles of IL-6 in ocular inflammation: a review. Ocul. Immunol. Inflamm. 26, 37\u201350 (2018).","journal-title":"Ocul. Immunol. Inflamm."},{"key":"99370_CR50","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/clpt.2009.252","volume":"88","author":"B Sassolas","year":"2010","unstructured":"Sassolas, B. et al. ALDEN, an algorithm for assessment of drug causality in Stevens\u2013Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin. Pharmacol. Ther. 88, 60\u201368 (2010).","journal-title":"Clin. Pharmacol. Ther."},{"key":"99370_CR51","doi-asserted-by":"publisher","first-page":"e1847","DOI":"10.1093\/milmed\/usaa029","volume":"185","author":"RE Newkirk","year":"2020","unstructured":"Newkirk, R. E., Fomin, D. A. & Braden, M. M. Erythema multiforme versus Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis: subtle difference in presentation, major difference in management.  Mil. Med. 185, e1847\u2013e1850 (2020).","journal-title":"Mil. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-99370-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-99370-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-99370-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T16:36:59Z","timestamp":1670085419000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-99370-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,12]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["99370"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-99370-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,12]]},"assertion":[{"value":"11 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20275"}}